Rotavirus is the leading cause of severe acute gastroenteritis in infants and young children globally — causing watery (non-bloody) diarrhoea, vomiting, fever and dehydration that can be fatal if untreated. In the absence of vaccination, virtually every child globally is infected by age 5. The disease burden falls overwhelmingly on children in LMICs without access to healthcare and rehydration. Two oral vaccines (Rotarix, RotaTeq) have transformed rotavirus mortality in vaccinated populations.

Why does rotavirus affect young children so severely?

Rotavirus infects the small intestinal epithelial cells — destroying the brush border villi responsible for fluid and nutrient absorption. The virus also produces NSP4 (non-structural protein 4), which acts as a viral enterotoxin, stimulating secretory diarrhoea. Young infants are most vulnerable because: they have no prior immunity; their smaller body size means even modest fluid losses cause severe dehydration rapidly; and they cannot communicate their symptoms or drink ORS independently.

How effective are rotavirus vaccines?

Rotarix and RotaTeq show dramatically different efficacy by setting: HICs (Europe, North America, Australia): 85-98% protection against severe rotavirus gastroenteritis. LMICs (Africa, Asia): 50-65% efficacy — lower but still highly significant and cost-effective. The lower LMIC efficacy is incompletely understood — possible factors include: higher background immunity from frequent natural infection; maternal antibodies; nutritional status; concomitant oral poliovirus vaccine; gut microbiome differences. Even at 50-65% efficacy, rotavirus vaccination in LMICs is highly cost-effective given the scale of mortality.

Is there any treatment for rotavirus?

No specific antiviral treatment exists. Management is entirely supportive: oral rehydration therapy (ORS) — the cornerstone of treatment; administered in small frequent amounts to replace ongoing losses; low-osmolarity WHO/UNICEF ORS formula is standard. If ORS fails (severe vomiting or dehydration): IV rehydration (Ringer's lactate or normal saline). Zinc supplementation (20mg/day for 10-14 days in LMICs): reduces diarrhoea duration and severity and prevents future diarrhoeal episodes. Probiotics (Lactobacillus rhamnosus GG): some evidence for modest reduction in duration.

Does improving WASH prevent rotavirus?

Surprisingly, no — rotavirus disease is not significantly reduced by improvements in water, sanitation and hygiene (WASH). This is because rotavirus is highly infectious at very low doses (capable of causing infection with 10-100 viral particles), is resistant to standard water chlorination, and can survive on surfaces for prolonged periods. Studies from countries with excellent WASH infrastructure show rotavirus disease patterns similar to countries with poor WASH. This WASH paradox means vaccination is the essential intervention — WASH improvements alone cannot reduce rotavirus burden.

How does GMJ News cover rotavirus?

GMJ News covers WHO rotavirus data, Rotarix and RotaTeq vaccine evidence, the WASH paradox, ORS treatment, GAVI vaccine access, and the pre- and post-vaccine mortality comparison. Rotavirus vaccination is a key component of Georgia's national immunisation schedule — directly relevant to PHIG's immunisation programme and child health priorities.

Home › Topics › Rotavirus

Rotavirus

GMJ News knowledge hub · last reviewed September 2026 · Georgian Medical Journal

Summary Statistics Glossary GMJ news FAQ Documents Organizations Research

Rotavirus — the leading cause of severe diarrhoeal disease in infants and young children — still causes over 200,000 deaths per year (predominantly in South Asia and Sub-Saharan Africa), reduced from approximately 500,000 before vaccine introduction; WHO has recommended universal inclusion of rotavirus vaccines in all national immunisation programmes since 2009, with Rotarix (GSK) and RotaTeq (Merck) providing approximately 85-98% protection against severe rotavirus gastroenteritis in HICs (WHO). Nearly every child globally is infected with rotavirus by age 5 without vaccination; the disease burden falls overwhelmingly on the poorest communities with inadequate access to safe water and oral rehydration.

Key messages

200K deaths/year — leading child diarrheal killer

Rotavirus causes over 200,000 deaths per year in children under 5 — predominantly in South Asia and Sub-Saharan Africa. Pre-vaccine, it killed approximately 500,000 children annually (WHO).

Vaccine works — 85-98% against severe disease in HICs

WHO-recommended rotavirus vaccines (Rotarix, RotaTeq) provide approximately 85-98% protection against severe rotavirus gastroenteritis in HICs and approximately 50-65% in LMICs — still preventing hundreds of thousands of deaths annually.

Every child infected by age 5 without vaccination

Rotavirus is ubiquitous — in the absence of vaccination, virtually every child globally acquires rotavirus infection by age 5. Natural infection induces partial immunity that reduces severity of subsequent infections.

ORS is the treatment — no specific antiviral

Treatment is oral rehydration therapy (ORS) to replace lost fluids and electrolytes. No specific antiviral treatment exists. Zinc supplementation reduces severity and duration in LMICs. Severe cases require IV fluids.

No water/sanitation protection — only vaccine works

Unlike most diarrheal diseases, rotavirus burden is not reduced by improvements in water, sanitation and hygiene (WASH) — this is because rotavirus is transmitted by contact with very small amounts of virus that survive standard disinfection. Only vaccination effectively prevents rotavirus disease.

Access gap in LMICs

Despite GAVI support, rotavirus vaccine coverage remains below 50% in high-burden Sub-Saharan African countries where the impact would be greatest. Rotavirus vaccines are on the WHO Essential Medicines List.

Key statistics

200K+

rotavirus deaths/year in children under 5 (post-vaccine era)

WHO

500K

annual deaths before rotavirus vaccine introduction

WHO

85-98%

rotavirus vaccine efficacy against severe disease (HICs)

WHO

50-65%

efficacy in LMICs (lower but still highly cost-effective)

WHO

Nearly 100%

of children infected by age 5 without vaccination

WHO

2009

year WHO recommended universal rotavirus vaccination

WHO

Rotavirus deaths in children under 5 by region — pre and post vaccine era

Source: WHO. South Asia and Sub-Saharan Africa account for approximately 80% of remaining rotavirus deaths.

Glossary of key terms

Rotavirus (RVA)
WHOA non-enveloped double-stranded RNA virus (Reoviridae, Rotavirus genus). Rotavirus A is responsible for approximately 90% of rotavirus disease in humans. Multiple G and P genotypes — G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8] cause approximately 90% of human disease. Rotavirus is highly stable in the environment.

Oral rehydration therapy (ORS)
WHO EMLWHO/UNICEF-formulated ORS — a glucose-sodium-potassium solution exploiting coupled glucose-sodium transport to replace fluid and electrolyte losses from diarrhoea. The single most life-saving medical innovation for diarrhoeal disease — cheap, effective, and deliverable at community level. Standard low-osmolarity ORS is the cornerstone of rotavirus disease management.

Rotarix (RV1)
GSK/WHOA live attenuated monovalent oral rotavirus vaccine — derived from a human G1P[8] strain. Administered in 2 doses (6 and 10 weeks). WHO pre-qualified. High efficacy in HICs; lower but clinically significant efficacy in LMICs. On WHO EML. Used in most GAVI-eligible countries.

RotaTeq (RV5)
Merck/WHOA live attenuated pentavalent oral rotavirus vaccine — containing five bovine-human reassortant strains (G1, G2, G3, G4, P[8]). Administered in 3 doses (2, 4, 6 months). WHO pre-qualified. High efficacy in HICs; comparable to Rotarix.

WASH paradox in rotavirus
WHOUnlike most diarrhoeal pathogens, rotavirus disease is NOT significantly reduced by improvements in water, sanitation and hygiene (WASH). This is because: rotavirus spreads through contact with tiny amounts of virus (faecal-oral — low infectious dose); rotavirus is resistant to standard water treatment (chlorination) and many surface disinfectants; and person-to-person contact transmission is important. Only vaccination effectively prevents rotavirus.

Rotavirus and intussusception
WHO/SafetyEarly rotavirus vaccines (RotaShield, Wyeth — withdrawn 1999) were associated with increased intussusception risk. Modern vaccines (Rotarix, RotaTeq) have a small (1-2 per 100,000 vaccinees) intussusception risk with the first dose — well below the risk from wild-type rotavirus disease. WHO safety surveillance confirms the benefit-risk balance strongly favours vaccination.